Menu Search
Equities

AVITA Medical Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
51KB:MUN

AVITA Medical Inc

Actions
  • Price (EUR)0.664
  • Today's Change0.00 / 0.00%
  • Shares traded600.00
  • 1 Year change-60.94%
  • Beta1.8438
Data delayed at least 15 minutes, as of Feb 13 2026 07:03 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

AVITA Medical, Inc. is a therapeutic acute wound care company. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.

  • Revenue in AUD (TTM)16.23m
  • Net income in AUD-40.56m
  • Incorporated2020
  • Employees87.00
  • Location
    AVITA Medical Inc28159 Avenue Stanford, Suite 220VALENCIA 91355United StatesUSA
  • Phone+1 (661) 367-9170
  • Websitehttps://www.avitamedical.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.